Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Inclusion Criteria:

* Male or female, of any racial or ethnic group
* Age 18 years or older
* Patient able and willing to provide informed consent
* Adequate kidney and liver function
* Karnofsky Performance Status ≥ 70%
* Negative serum pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control
* Imaging suggestive of malignant glioma (Cohort A)
* History of glioma with measurable disease by MRI (Cohorts B and C)
* Histologically confirmed GBM with radiographic progression (Cohort B). These patients are permitted to have had prior therapy including surgery, radiation, Temozolomide, irinotecan and bevacizumab.
* Histological confirmation of a low-grade glioma (Cohort C)

Exclusion Criteria:

* Patient unable to provide informed consent (comatose or markedly cognitively impaired)
* Female participants that are pregnant or breastfeeding
* Any other concurrent anticancer therapy
* Karnofsky Performance status \< 70%
* Any other concurrent investigational agents within 4 weeks of start of study drug
* Patients with liver disease (known or active Hepatitis B or C; steatohepatitis; cirrhosis)
* Hepatic:

  * Bilirubin greater than 1x the upper limit of normal
  * Transaminases greater than 1x the upper limit of normal
* Abnormal renal function

  o Serum creatinine \>1.7 ng/dl
* Patients on concomitant medications that induce or inhibit CYP450, such as enzyme inducing anti-epileptic drugs (EIAEDs) (Appendix III) and troglitazone